Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease - 03/09/11
Abstract |
Background The Glu298Asp polymorphism of endothelial nitric oxide synthase (eNOS) gene has been associated with coronary artery disease (CAD) in some but not all studies. To determine the impact of the mutant Asp298 eNOS allele on the development of premature CAD, we examined the prevalence of this mutation in patients with early-onset CAD compared with those manifesting CAD later in life. If this mutation confers an increased risk of premature CAD, we hypothesized that the frequency of the homozygous mutation (Asp298Asp298) would be greater among the younger patient group. Methods A total of 299 patients with a history of myocardial infarction (MI) or angina pectoris plus angiographically documented CAD were studied. Patients were divided into 2 groups: group 1 (149 patients) included patients with CAD before the age of 50 years and group 2 (150 patients) included patients with a first presentation of CAD at >65 years old. Prevalence of eNOS Glu298 and Asp298 alleles was assessed by molecular analysis and compared for the 2 groups. Results There was no significant difference in the frequency of the mutant Asp298 allele between the 2 groups (G1: 42% vs G2: 42.7%, P =.79). The frequencies of the Glu298Glu298, Glu298Asp298, and Asp298Asp298 genotypes were similar in both groups (34.9%, 46.3%, and 18.8% for G1 and 29.3%, 56%, and 14.7% for G2, respectively, P =.29). Conclusions Our study does not support the conclusion that the eNOS Asp298 allele contributes to the development of premature CAD. (Am Heart J 2001;142:586-9.)
Le texte complet de cet article est disponible en PDF.Plan
| ☆ | Supported in part by a grant from the Cardiac Prevention Research Centre at Queen Elizabeth II Health Sciences Centre. |
| ☆☆ | Reprint requests: Bassam A. Nassar, PhD, MB BCh, Division of Clinical Chemistry, Department of Pathology and Laboratory Medicine, Queen Elizabeth II Health Sciences Centre, 1278 Tower Road, Halifax, NS B3H 2Y9, Canada. E-mail: plmban@qe2-hsc.ns.ca |
Vol 142 - N° 4
P. 586-589 - octobre 2001 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
